Safety and immunogenicity profile of human papillomavirus-16/18 as04 adjuvant cervical cancer vaccine: A randomized controlled trial in healthy adolescent girls of Bangladesh

Japanese Journal of Clinical Oncology

Volumn 42, Issue 1, 2012, Pages 36-41

  Khatun, Sabera ^a   Akram Hussain, Syed Md ^a   Chowdhury, Sameena ^a   Ferdous, Jannatul ^a   Hossain, Fawzia ^a   Begum, Sultana Razia ^a   Jahan, Munira ^a   Tabassum, Shahina ^a   Khatun, Shahla ^b   Fazlul Karim, A B M ^c  

^a BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

^b Bangladesh Medical College   (Bangladesh)

^c Japan Bangladesh Friendship Hospital   (Bangladesh)

Author keywords

AS04 adjuvanted vaccine; Cervical cancer prevention; HPV 16 18; Immunogenicity; Randomized trial; Safety

Indexed keywords

CANCER VACCINE; HUMAN PAPILLOMAVIRUS TYPE 16 ANTIBODY; HUMAN PAPILLOMAVIRUS TYPE 18 ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROCONVERSION; UTERINE CERVIX CANCER; VACCINATION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ANTIBODIES, VIRAL; BANGLADESH; CHILD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84555187428     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr173     Document Type: Article

References (29)

1. Boyle P, Levin B. World Cancer Report 2008. International Agency for Research on Cancer 2008;128-9.
2. Globocan. International Agency for Research on Cancer 2008. Bangladeshdata.iarc.factsheets.pdf.
3. Dinshaw K, Mishra G, Shastri S. Determinants of compliance in a cluster randomised controlled trial on screening of breast and cervix cancer in Mumbai, India.1. Compliance to screening. Oncology 2007;73:145-53.
4. Bosch FX, de Sanjose S. Chapter 1: human papilloma virus and cervical cancer-burden and assessment of causality. J Natl cancer Inst Monogr 2003;1:3-13.
5. Ashrafunnessa, Khatun SS, Chowdhury TA, Shamsuddin L, Islam MN, Hassan MS, et al. Human papilloma virus in cervical intraepithelial neoplasia in Bangladesh. Bangladesh J Obstet Gynaecol 2005;20:13-8.
6. Akter M, Prevalence of HPV infection in apparently healthy woman. Dissertation of FCPS Part II Examination of BCPS 2010.
7. Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, et al. Prevalence and determinants of genital infection with papilloma virus, in female and male university students in Busan, South Korea. J Infect Dis 2004;190:468-76.
8. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistence genital human papilloma virus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Int 1995;87:1365-71.
9. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, et al. Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.
10. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, et al. Type-specific persistence of human papilloma virus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8.
11. Zur Hausen H. Immortalization of human cells and their malignant conversion by high risk human papilloma virus genotypes. Semin Cancer Biol 1999;9:405-11.
12. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA, et al. Genital human papilloma virus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26.
13. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papilloma virus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010;102:325-39.
14. Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res 2010;36:123-32.
15. Montefiori DC, Match B, McElrath MJ, Self S, Weinhold KJ, Corey L, et al. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infec Dis 2004;190:1962-9.
16. Giannini SL, Hanon E, Moris P, Mechelen MV, Morel S, Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24:5937-49.
17. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix and GardasilR human papilloma virus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccine 2009;5:705-19.
18. Plummer M, Franceschi S. Strategies for HPV prevention. Virus Res 2002;89:285-93.
19. Cancer Registry Report. National Institute of Cancer Research and Hospital, World Health Organization, Country Office for Bangladesh 2005-2007;15.
20. Das BC, Hussain S, Nasare V, Bharadwaj M. Prospects and prejudices of human papilloma virus vaccines in India. Vaccine 2008;26:2669-79.
21. Ghim SJ, Basu PS, Jenson A. Cervical cancer: etiology, pathogenesis, treatment, and future vaccines. Asian Pac J Cancer Prev 2002;3: 207-12.
22. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. HPV PATRICIA Study Group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papilloma virus types 16 and 18 in young women: an interim analysis of a phase III double-blind randomised controlled trial. Lancet 2007;369:2161-70.
23. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papilloma virus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
24. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjosé S, Hammouda D, et al. Against which human papilloma virus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278.
25. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med 2007;356:1928-43.
26. FUTURE II Study Group. Quadrivalent vaccine against human papilloma virus to prevent high-grade cervical lesions. New Engl J Med 2007;356:1915-27.
27. Paavonen J, The FUTURE II Study Group. The impact of baseline subject characteristics on the efficacy, safety and immunogenicity of a quadrivalent (types 6,11,16,8) human papillomavirus (HPV) L1 virus like particle vaccine. In: Presented at the 46th Interscience Conference on Antimicrobbial Agents and Chemotherapy (ICAAC), San Francisco, CA, 27 September 2006.
28. Vallikad E. Cervical cancer: the Indian perspective. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95:S215-33.
29. Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008;99:230-38.